Cytokinetics Files 8-K for Financial Results and Operations
Ticker: CYTK · Form: 8-K · Filed: Feb 27, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financial-report, 8-K, disclosure
Related Tickers: CYTK
TL;DR
**Cytokinetics just filed an 8-K for their financial results, so expect detailed performance data soon.**
AI Summary
Cytokinetics, Incorporated filed an 8-K on February 27, 2024, to report on its results of operations and financial condition. This standard disclosure also includes financial statements and exhibits, signaling an upcoming release of detailed financial performance data. Specific dollar amounts or detailed results are not provided in this initial filing excerpt.
Why It Matters
This filing signals the release of Cytokinetics' latest financial performance, providing investors with crucial data to assess the company's health and future prospects, potentially impacting stock valuation.
Risk Assessment
Risk Level: medium — The filing itself is a standard disclosure, but the actual financial results, which are not detailed in this excerpt, could introduce market volatility.
Key Players & Entities
- Cytokinetics, Incorporated (company) — Registrant
- 03 Life Sciences (company) — Organization Name
- South San Francisco (location) — Business Address City
- California (location) — Business Address State
FAQ
What is the earliest event date reported in this 8-K filing?
The earliest event reported in this 8-K filing is February 27, 2024.
What is the full legal name of the registrant company?
The exact name of the registrant as specified in its charter is Cytokinetics, Incorporated.
What specific items are being reported in this 8-K filing?
This 8-K filing reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the business address of Cytokinetics, Incorporated?
The business address of Cytokinetics, Incorporated is 350 Oyster Point Boulevard, South San Francisco, California, 94080.
What is the telephone number for Cytokinetics, Incorporated?
The telephone number for Cytokinetics, Incorporated is (650) 624-3000.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-02-27 16:05:22
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20240227.htm (8-K) — 36KB
- cytk-ex99_1.htm (EX-99.1) — 219KB
- img114956760_0.jpg (GRAPHIC) — 8KB
- 0000950170-24-021099.txt ( ) — 392KB
- cytk-20240227.xsd (EX-101.SCH) — 24KB
- cytk-20240227_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 27, 2024, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2023. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered "filed" under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated February 27, 2024 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: February 27, 2024 By: /s/ John O. Faurescu John O. Faurescu, Esq. Associate General Counsel & Secretary